lifileucel | sciencenewsnet.in

Breaking News

American Joint Replacement Registry Surpasses 4 Million Captured Hip and Knee Arthroplasty Procedures

Scientists Capture Images of Electron Molecular Crystals

Does more virtual care mean more low-value care? Study suggests no

New Survey from Heterodox Academy and College Pulse of 1,500+ Canadian Undergraduates Shows Fear of Free Expression on Campus

Mayo Clinic researchers recommend alternatives to hysterectomy for uterine fibroids, according to study

New AI-based natural language feature makes complex searches in Dimensions faster and easier

Atomic-level heterostructures for enhanced photocatalytic hydrogen evolution

INSCRIPTA® ANNOUNCES BIOMANUFACTURING OF A RAPIDLY GROWING ANTI-AGING SKINCARE INGREDIENT

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Population genetic characteristics of two hybrid crucian carp strains

07 Nov, 2024

Sylvester Cancer Adding Cellular Therapy to Its Arsenal Against Metastatic Melanoma

May 1, 2024 sarah JonasAnnouncement

Patients in South Florida with metastatic melanoma will soon have access to tumor-infiltrating lymphocyte therapy, or TIL. The therapy will be available at Sylvester Comprehensive Cancer Center and will be South Florida’s only center offering this treatment.

Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma

February 19, 2024 sarah JonasResearch Results

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.